# Updated standard operating procedures for electrochemotherapy of cutaneous tumours and skin metastases

Source: https://onco.cc/key-papers/paper-gehl-acta-oncol/  
OnCo record `paper-gehl-acta-oncol` (Key paper). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Paper cited by one technology page, indexed on Europe PMC as PubMed record 29577784 and published in Acta oncologica; the citing page links this DOI, which is how the record was matched.

## Summary

Electrochemotherapy is now in routine clinical use to treat cutaneous metastases of any histology, and is listed in national and international guidelines for cutaneous metastases and primary skin cancer. Electrochemotherapy is used by dermatologists, surgeons, and oncologists, and for different degrees and manifestations of metastases to skin and primary skin tumours not amenable to surgery. This treatment utilises electric pulses to permeabilize cell membranes in tumours, thus allowing a dramatic increase of the cytotoxicity of anti-cancer agents. Response rates, often after only one treatment, are very high across all tumour types. The most frequent indications are cutaneous metastases from malignant melanoma and breast cancer. In 2006, standard operating procedures (SOPs) were written for this novel technology, greatly facilitating introduction and dissemination of the therapy. Since then considerable experience has been obtained treating a wider range of tumour histologies and increasing size of tumours which was not originally thought possible. A pan-European expert panel drawn from a range of disciplines from dermatology, general surgery, head and neck surgery, plastic surgery, and oncology met to form a consensus opinion to update the SOPs based on the experience obtained. This paper contains these updated recommendations for indications for electrochemotherapy, pre-treatment information and evaluation, treatment choices, as well as follow-up.

Indexed on Europe PMC as PubMed record 29577784 (DOI 10.1080/0284186x.2018.1454602). Matched by DOI alone: one technology page cites this DOI among its external links (the pages are listed under Related), and this page was written so that the citation resolves inside OnCo. No figure has been checked by an editor.

## Fields

- Kind: Key paper
- Last checked: 2026-09-22
- Tags: europepmc-ingest
- Journal: Acta oncologica
- Year: 2018
- DOI: 10.1080/0284186x.2018.1454602
- Authors: Gehl J, Sersa G, Matthiessen LW, et al.
- What it means: One technology page on OnCo cites this paper by its DOI; this record gives the citation a page of its own so a reader can follow it without leaving OnCo. Read the abstract above alongside the citing page listed under Related; the record was created automatically from the Europe PMC entry and its figures have not been checked by hand.
- Caveats: Matched to the citing OnCo records by DOI alone; the summary reproduces the Europe PMC abstract and no figure has been verified against the full paper.

## Sources

- Acta Oncol 2018: https://doi.org/10.1080/0284186x.2018.1454602
- PubMed: https://pubmed.ncbi.nlm.nih.gov/29577784/
- Europe PMC: https://europepmc.org/article/MED/29577784

## Connected records

- technologies: [Electrochemotherapy devices (Cliniporator)](https://onco.cc/technologies/electrochemotherapy-devices/)
- journals: [Acta oncologica](https://onco.cc/journals/acta-oncologica/)

---
JSON: https://onco.cc/api/v1/entities/paper-gehl-acta-oncol.json